Researchers engineer T cells to recognize tumor-specific expression patterns, enhancing tumor response

June 27, 2018, Baylor College of Medicine
Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAID

The advent and advancement of T cell therapy, especially chimeric antigen receptor (CAR)-modified T cells, has demonstrated therapeutic potential in treating previously treatment-resistant tumors. However, few CAR targets are absolutely tumor-specific, resulting in "on-target, off-tumor" toxicities that can be severe. Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist have found a new way to ensure that engineered T cells can reliably discriminate between normal and malignant cells. This was achieved by modifying T cells to express a trio of molecules designed to recognize a pattern of antigens that are present, in combination, only on tumor cells. When tested in preclinical studies, these engineered T cells exhibited enhanced anti-tumor activity and selectivity, without side effects. The study appears in Cancer Discovery.

"In the past, CAR T cell therapy has worked through the specific targeting of a single antigen present on the surface. However, this can be limiting, and even result in toxicity, when the CAR T cells find the antigen on normal tissues, which is called 'on-target, off-tumor,'" said Dr. Juan Vera, associate professor in the Center for Cell and Gene Therapy at Baylor. "In this study, we engineer CAR T cells to recognize a cohort, or a pattern, of molecules uniquely present in the . What this means is that our 'smarT cells' are able to better discriminate between tumor-proliferating cells and bystander cells."

In addition to a lack of signature, traditional T cell therapy also has been limited by the suppressive nature of the tumor microenvironment, which limits the long-term survival and population growth of the T cells in solid tumors.

The research team chose to incorporate receptors into their engineered T cells that would protect them from such suppressive elements and ensure their sustained tumor killing capacity until all were eliminated.

"The tumor signature detected by these smarT cells results in the delivery of three key signals to T cells: antigen activation, co-stimulation, and cytokine, which are delivered in a manner similar to physiological T cell activation," said Vera, who also is a member of the Dan L Duncan Comprehensive Cancer Center at Baylor. "When the T cells detect the signature, they are activated and grow and expand at the tumor site. Simultaneously, these signals congregate T cells resistant to the inhibitory effects of the tumor site and ensure their sustained long-term survival and effector function."

Engineering T cells to recognize tumor patterns is an example of the next generation of genetic editing, where engineered T cells are emulating the natural T cell response as closely as possible.

"Our study demonstrates the feasibility of reprogramming T cells to recognize a signature rather than a single antigenic marker expressed by tumors, thus enabling our modified cells to specifically target malignant tissues. By utilizing sophisticated genetic engineering approaches, we designed synthetic receptors that enhance both the potency and safety profile of the infused , which are key factors that underlie the success of CAR T cell therapy," said Dr. Sujita Sukumaran, first author on the paper and now a scientist in the T cell engineering group at Kite Pharma, Inc.

Explore further: Results of glioblastoma clinical trial show safety and clinical benefit of CAR T cell therapy

More information: Sujita Sukumaran et al. Enhancing the potency and specificity of engineered T cells for cancer treatment, Cancer Discovery (2018). DOI: 10.1158/2159-8290.CD-17-1298

Related Stories

Results of glioblastoma clinical trial show safety and clinical benefit of CAR T cell therapy

April 21, 2017
Glioblastoma is the most common brain tumor in humans and also one of the most difficult cancers to treat; patients with this type of cancer only survive about one year from time of diagnosis. Researchers at Baylor College ...

Special T cells that target solid tumors offer potential treatment for pediatric and adult cancers

September 14, 2016
Adoptive cell-therapies, in which a patient's own immune cells are used to recognize and target tumors, have shown breakthrough results for patients with certain B-cell malignancies, or cancers of the blood, but this therapy ...

A new T-cell population for cancer immunotherapy

May 23, 2017
Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells. The open access journal eLife has published the results.

New receptor genes turn T-cells into powerful liver cancer foes

April 3, 2018
Mouse genes that make human T cells powerful at fighting liver cancer could one day help patients do the same, scientists report.

Engineered T cells kill tumors but spare normal tissue in an animal model

April 7, 2013
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs. Tumor antigens, unique proteins on the surface of a tumor, are potential targets for a normal ...

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.